Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
77314.000.1375%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Travere Therapeutics Inc (TVTX) Stock Price, Quote, News & History

TVTXNASDAQ
Trade with Public
Trade with Public
$66.17
-1.34-1.98%
At close: Sep 11, 5:00 PM EST
$66.17
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Travere Therapeutics (TVTX) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$67.76
Close
$66.17
Volume / Avg.
1.15M / 1.69M
Day Range
$66.11 - $68.73
52 Wk Range
22.06 - 68.59
Market Cap
$6.15B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
57
Short Interest
16.88%
Days to Cover
9.56

Recent Travere Therapeutics, Inc. News

Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday

US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies recording gains in today's session.
Avi Kapoor

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.
Mohd Haider

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.
Avi Kapoor

Crude Oil Falls Sharply; Wells Fargo Earnings Miss Views

Dow Jones up 200 points, consumer discretionary shares rise 1.8%, Wells Fargo reports worse-than-expected earnings, Avanos Medical surges 69%.
Avi Kapoor

Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday

Dow Jones up 200 points, Avanos Medical Inc rose on going-private deal. Big gainers include AVNS, TVTX, BE, IONQ, SANA, RGTI, VACH, AOSL.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
92.70M
Investing Cash Flow (TTM)
-202.99M
Financing Cash Flow (TTM)
153.06M
Free Cash Flow (TTM)
15.16M
Capital Expenditure (TTM)
-77.54M
Net Change in Cash (TTM)
42.78M

Analyst Trends and Forecast

5
May
8
Jun
1
Jul
7
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$6.36B
PE Ratio (TTM)
-
PE Ratio (FWD)
45.05
PEG Ratio (TTM)
-
PS Ratio (TTM)
10.41
PB Ratio (TTM)
259.50
Earnings Yield % (TTM)
-1.08%
Earnings Yield % (FWD)
2.22%
EV / EBITDA (TTM)
1123.64
Price / EBITDA (TTM)
1066.05
Price / Free Cash Flow (TTM)
406.13
Book Value / Share
$0.26

Company Debt

Total Debt
$602.78M
LT Debt
$602.78M
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$419.79M
Total Cash
$117.74M
Debt to Equity
25.16
Issuance of Debt (TTM)
$105.21M
Repayment of Debt (TTM)
-$419.79M

Key Statistics

Open
$67.76
Close
$66.17
Volume / Avg.
1.15M / 1.69M
Day Range
$66.11 - $68.73
52 Wk Range
22.06 - 68.59
Market Cap
$6.15B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
57
Short Interest
16.88%
Days to Cover
9.56

About

Sector
Health Care
Industry
Biotechnology
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Travere Therapeutics (TVTX) stock?

A

You can purchase shares of Travere Therapeutics (NASDAQ:TVTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Travere Therapeutics (TVTX) competitors?

Q

What is the forecast, or price target, for Travere Therapeutics (TVTX) stock?

A

Travere Therapeutics has a consensus price target of $49.39.

Q

What is the current price for Travere Therapeutics (TVTX)?

A

The stock price for Travere Therapeutics (NASDAQ: TVTX) is $66.17 last updated September 11, 2026 at 4:00 PM EDT.

Q

Does Travere Therapeutics (TVTX) pay a dividend?

A

There are no upcoming dividends for Travere Therapeutics.

Q

When is Travere Therapeutics (NASDAQ:TVTX) reporting earnings?

A

Travere Therapeutics does not have any upcoming earnings scheduled.

Q

Is Travere Therapeutics (TVTX) going to split?

A

There is no upcoming split for Travere Therapeutics.

Q

What sector and industry does Travere Therapeutics (TVTX) operate in?

A

Travere Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved